Revolution Medicines, Inc. reiterated earnings guidance for the full year 2024. The company is reiterating its projected full year 2024 GAAP net loss to be between $480 million and $520 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.13 USD | -4.12% | -2.21% | +32.95% |
May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.95% | 6.56B | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024